Brunei vs Tonga: Statin use vs. average non-HDL cholesterol levels

Brunei
3.8
in 2018
Tonga
3.8
in 2018
Brunei rank
6th
Tonga rank
6th

Statin use vs. average non-HDL cholesterol levels over time

  • Brunei
  • Tonga
01234198019992018

How they compare

Brunei currently reports 3.8 against 3.8 in Tonga, a difference of 0.

The two have swapped places 1 time across 39 shared years of data; in 1980 it was Brunei ahead.

Brunei ranks 6th and Tonga ranks 6th of 191 countries.

Across the 4 decades both report, Brunei averaged higher in 1 and Tonga in 2.

Head to head by decade

Decade Brunei Tonga Difference Ahead
1980s 3.76 3.6 0.16 Brunei
1990s 3.7 3.78 0.08 Tonga
2000s 3.77 3.8 0.03 Tonga
2010s 3.8 3.8 0

Averages of every year both report within each decade.

Frequently asked questions

Which has higher statin use vs. average non-hdl cholesterol levels, Brunei or Tonga?
Brunei, at 3.8 against 3.8 in Tonga as of 2018.
What is the difference in statin use vs. average non-hdl cholesterol levels between Brunei and Tonga?
0, with Brunei ahead.
How many years of comparable data are there for Brunei and Tonga?
39 years are reported by both, from 1980 to 2018.
How do Brunei and Tonga rank globally for statin use vs. average non-hdl cholesterol levels?
Brunei ranks 6th and Tonga ranks 6th of 191 countries.
Where does this data come from?
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

About this data

Indicator
Statin use vs. average non-HDL cholesterol levels
Source
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
191 places, 7,449 data points, 1980–2018
Last refreshed

The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.